Genetic Future's Daniel MacArthur discusses the 23andMe's recent "lab mix-up [that] resulted in as many as 96 customers receiving the wrong data." In his analysis of the 23andMe announcement (accessible only to registered users), MacArthur opines that likely a single 96-well plate was affected, which "resulted in incorrect results bein

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.